Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.12 AUD | +1.36% |
|
+12.00% | +261.29% |
02/07 | Mesoblast to File Biological License Application with US FDA for Cellular Therapy | MT |
01/07 | Mesoblast to File Biologics License Application for Ryoncil | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+261.29% | 851M | |
+18.97% | 45.34B | |
+42.78% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- MSB Stock
- News Mesoblast Limited
- Transcript : Mesoblast Limited, Q4 2021 Earnings Call, Aug 30, 2021